Loading
A phase 2 trial of Zelenectide pevedotin, Pembrolizumab, Carboplatin, Cisplatin, Gemcitabine and Gemcitabine + cisplatin in bladder & urothelial cancer, run by BicycleTx Limited, active and no longer recruiting.
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) is a phase 2 interventional study registered as NCT06225596 by BicycleTx Limited, with 375 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-03. Interventions recorded: Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin and Avelumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates and the tag pipeline.
Shares Zelenectide pevedotin, Bicycle Therapeutics, Peptide-drug & small-molecule-drug conjugates, Bladder & urothelial cancer and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Shares Muscle-invasive and advanced bladder cancer, Gemcitabine, Bladder & urothelial cancer, Cisplatin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/